Insights Into Eli Lilly and Co's Performance Versus Peers In Pharmaceuticals Sector
Portfolio Pulse from Benzinga Insights
Eli Lilly and Co (NYSE:LLY) is evaluated against its peers in the Pharmaceuticals industry. The company shows high PE, PB, and PS ratios, indicating potential overvaluation. However, it has strong ROE and revenue growth, suggesting profitability and future prospects. Concerns arise from lower EBITDA and gross profit, and a high debt-to-equity ratio indicates financial risk.
June 28, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Eli Lilly and Co (NYSE:LLY) has high PE, PB, and PS ratios, indicating potential overvaluation. Strong ROE and revenue growth suggest profitability and future prospects. However, lower EBITDA and gross profit, along with a high debt-to-equity ratio, raise concerns about financial risk.
The high valuation ratios (PE, PB, PS) suggest that the stock might be overvalued, which could lead to a neutral or negative short-term impact. However, the strong ROE and revenue growth are positive indicators. The lower EBITDA and gross profit, along with a high debt-to-equity ratio, introduce financial risk, balancing the overall impact to neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100